Low-Dose Bevacizumab Atezolizumab TACE-HAIC for HCC
Summary
This is a prospective, single-arm, Phase II clinical study (NCT07543510) evaluating the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion chemotherapy (TACE-HAIC) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The study plans to enroll approximately 38 patients with unresectable, locally advanced HCC who have not received prior systemic therapy. The primary endpoint is objective response rate (ORR) assessed by investigators according to RECIST version 1.1.
“The primary endpoint is objective response rate (ORR) assessed by investigators according to RECIST version 1.1.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 715 changes logged to date.
What changed
This ClinicalTrials.gov registration describes a prospective, single-arm, Phase II clinical study evaluating a combination regimen of low-dose bevacizumab and atezolizumab with transarterial chemoembolization followed by hepatic arterial infusion chemotherapy (TACE-HAIC) in approximately 38 patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. The study aims to explore whether TACE-HAIC can improve objective response rates by increasing local chemotherapy exposure and enhancing the anti-tumor activity of immunotherapy and anti-angiogenic therapy. Secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Clinical investigators conducting oncology or hepatocellular carcinoma research should be aware of this trial as it represents an investigational combination approach evaluating the synergy between locoregional therapy and systemic immunotherapy for advanced HCC.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
N/A NCT07543510 Kind: NA Apr 22, 2026
Abstract
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion chemotherapy (TACE-HAIC) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The study plans to enroll approximately 38 patients with unresectable, locally advanced HCC who have not received prior systemic therapy.
Although atezolizumab plus bevacizumab has become a standard first-line treatment option for advanced HCC, the objective response rate remains limited. TACE-HAIC may improve tumor control by increasing local chemotherapy exposure, promoting tumor antigen release, and enhancing the anti-tumor activity of immunotherapy and anti-angiogenic therapy. In this study, patients will receive TACE-HAIC in combination with atezolizumab and low-dose bevacizumab, followed by maintenance treatment with atezolizumab plus low-dose bevacizumab until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria.
The primary endpoint is objective response rate (ORR) assessed by investigators according to RECIST version 1.1. Secondary endpoints include ORR by mRECIST, disease control rate, duration of response, progression-free survival, time to progression, overall survival, and safety. This study aims to explore whether this combination strategy can provide improv...
Conditions: Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
Interventions: TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
Named provisions
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.